Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - bryst neoplasmer - antineoplastiske midler - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - andre alimentary tract and metabolism produkter, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

valneva sweden ab - rekombinant kolera toxin b underenhed, vibrio cholerae 01 - cholera; immunization - vacciner - dukoral er indiceret til aktiv immunisering mod sygdom forårsaget af vibrio cholerae serogruppe o1 hos voksne og børn fra 2 år, der vil besøge endemiske / epidemiske områder. brug af dukoral bør fastsættes på grundlag af de officielle anbefalinger under hensyntagen til variabiliteten i epidemiologi og risikoen for at pådrage sig sygdommen i forskellige geografiske områder og rejser betingelser. dukoral bør ikke erstatte standard beskyttelsesforanstaltninger. i tilfælde af diarré foranstaltninger af rehydrering bør anlægges.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

allergan pharmaceuticals international limited - eluxadoline - irritable bowel syndrome; diarrhea - antidiarrémidler, tarm antiinflammatorisk / antiinfective agenter - truberzi er indiceret hos voksne til behandling af irritabel tarmsyndrom med diarré (ibs d).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - linezolid - infusionsvæske, opløsning - 2 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

tillotts pharma gmbh - fidaxomicin - clostridiuminfektioner - antidiarrémidler, tarm antiinflammatorisk / antiinfective agenter - dificlir filmovertrukne tabletter er indiceret til behandling af clostridioides difficile infektioner (cdi) også kendt som c. difficile-associeret diaré (cdad) hos voksne og pædiatriske patienter med en kropsvægt på mindst 12. 5 kg. bør der tages hensyn til de officielle retningslinjer for korrekt brug af antibakterielle midler.. dificlir granulat til oral suspension er indiceret til behandling af clostridioides difficile infektioner (cdi) også kendt som c. difficile-associeret diaré (cdad) hos voksne og pædiatriske patienter fra fødsel til < 18 år. bør der tages hensyn til de officielle retningslinjer for korrekt brug af antibakterielle midler..

Den Europæiske Union - dansk - EMA (European Medicines Agency)

serb sas - telotristat etiprat - carcinoid tumor; neuroendocrine tumors - andre fordøjelseskanaler og stofskifteprodukter - xermelo er indiceret til behandling af carcinoid syndrom diarré i kombination med somatostatinanalog (ssa) behandling hos voksne, som ikke er tilstrækkeligt kontrolleret ved ssa-terapi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - bryst neoplasmer - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastiske midler - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.